Icure Pharmaceutical Incorporation (175250) — Cash Flow Reinvestment Rate

Latest as of June 2020: 83.70x

Icure Pharmaceutical Incorporation (175250) has a Cash Flow Reinvestment Rate of 83.70x as of June 2020, reinvesting ₩16.36 Billion (capex ₩7.44 Billion plus investments ₩8.92 Billion) from operating cash flow of ₩195.44 Million. Explore 175250 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

83.70x
(Capex + Investments) / Operating CF

Total Reinvested

₩16.36 Billion
Capex + Investments

Operating Cash Flow

₩195.44 Million
KRW

Capital Expenditures

₩7.44 Billion
KRW

Icure Pharmaceutical Incorporation Cash Flow Reinvestment Rate (2017–2017)

Historical reinvestment intensity for Icure Pharmaceutical Incorporation across 1 annual periods. Also explore 175250 total asset value for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Icure Pharmaceutical Incorporation (2017–2017)

Year-by-year capital reinvestment analysis for Icure Pharmaceutical Incorporation. For live market cap and broader valuation context, see Icure Pharmaceutical Incorporation market capitalisation.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2017 9.20x ₩10.30 Billion ₩1.12 Billion ₩10.10 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow